Modelling A.I. in Economics

AMED Stock: Is It a Bubble?

Outlook: Amedisys Inc Common Stock is assigned short-term Ba2 & long-term Ba2 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Sell
Time series to forecast n: for Weeks2
Methodology : Transductive Learning (ML)
Hypothesis Testing : Independent T-Test
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.


Summary

AMED stock is the stock of Amedisys, Inc., a healthcare services company that provides home health care, hospice, and personal care services. The company is headquartered in Baton Rouge, Louisiana, and has over 25,000 employees. AMED stock is traded on the New York Stock Exchange under the ticker symbol "AMED". As of March 8, 2023, AMED stock is trading at $125.10 per share. The company has a market capitalization of over $11 billion. AMED stock has been on a downward trend since reaching a high of $190.60 per share in February 2023. Analysts have given AMED stock a mixed rating. Some analysts believe that the company is undervalued and that the stock price will rebound in the future. Others believe that the company is overvalued and that the stock price is due for a correction. Overall, AMED stock is a volatile stock that is subject to a wide range of factors. Investors should carefully consider the risks and rewards before investing in AMED stock. Amedisys Inc Common Stock prediction model is evaluated with Transductive Learning (ML) and Independent T-Test1,2,3,4 and it is concluded that the AMED stock is predictable in the short/long term. Transductive learning is a supervised machine learning (ML) method in which the model is trained on both labeled and unlabeled data. The goal of transductive learning is to predict the labels of the unlabeled data. Transductive learning is a hybrid of inductive and semi-supervised learning. Inductive learning algorithms are trained on labeled data only, while semi-supervised learning algorithms are trained on a combination of labeled and unlabeled data. Transductive learning algorithms can achieve better performance than inductive learning algorithms on tasks where there is a small amount of labeled data. This is because transductive learning algorithms can use the unlabeled data to help them learn the relationships between the features and the labels.5 According to price forecasts for 4 Weeks period, the dominant strategy among neural network is: Sell

Graph 49

Key Points

  1. Transductive Learning (ML) for AMED stock price prediction process.
  2. Independent T-Test
  3. Operational Risk
  4. Can statistics predict the future?
  5. Operational Risk

AMED Stock Price Forecast

We consider Amedisys Inc Common Stock Decision Process with Transductive Learning (ML) where A is the set of discrete actions of AMED stock holders, F is the set of discrete states, P : S × F × S → R is the transition probability distribution, R : S × F → R is the reaction function, and γ ∈ [0, 1] is a move factor for expectation.1,2,3,4


Sample Set: Neural Network
Stock/Index: AMED Amedisys Inc Common Stock
Time series to forecast: 4 Weeks

According to price forecasts, the dominant strategy among neural network is: Sell


F(Independent T-Test)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Transductive Learning (ML)) X S(n):→ 4 Weeks e x rx

n:Time series to forecast

p:Price signals of AMED stock

j:Nash equilibria (Neural Network)

k:Dominated move of AMED stock holders

a:Best response for AMED target price


Transductive learning is a supervised machine learning (ML) method in which the model is trained on both labeled and unlabeled data. The goal of transductive learning is to predict the labels of the unlabeled data. Transductive learning is a hybrid of inductive and semi-supervised learning. Inductive learning algorithms are trained on labeled data only, while semi-supervised learning algorithms are trained on a combination of labeled and unlabeled data. Transductive learning algorithms can achieve better performance than inductive learning algorithms on tasks where there is a small amount of labeled data. This is because transductive learning algorithms can use the unlabeled data to help them learn the relationships between the features and the labels.5 An independent t-test is a statistical test that compares the means of two independent samples. In an independent t-test, the data points in each sample are not related to each other. The independent t-test is a parametric test, which means that it assumes that the data is normally distributed. The independent t-test is also a two-sample test, which means that it compares the means of two independent samples.6,7

 

For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

AMED Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

Financial Data Adjustments for Transductive Learning (ML) based AMED Stock Prediction Model

  1. However, the designation of the hedging relationship using the same hedge ratio as that resulting from the quantities of the hedged item and the hedging instrument that the entity actually uses shall not reflect an imbalance between the weightings of the hedged item and the hedging instrument that would in turn create hedge ineffectiveness (irrespective of whether recognised or not) that could result in an accounting outcome that would be inconsistent with the purpose of hedge accounting. Hence, for the purpose of designating a hedging relationship, an entity must adjust the hedge ratio that results from the quantities of the hedged item and the hedging instrument that the entity actually uses if that is needed to avoid such an imbalance
  2. Rebalancing refers to the adjustments made to the designated quantities of the hedged item or the hedging instrument of an already existing hedging relationship for the purpose of maintaining a hedge ratio that complies with the hedge effectiveness requirements. Changes to designated quantities of a hedged item or of a hedging instrument for a different purpose do not constitute rebalancing for the purpose of this Standard
  3. If a put option written by an entity prevents a transferred asset from being derecognised and the entity measures the transferred asset at fair value, the associated liability is measured at the option exercise price plus the time value of the option. The measurement of the asset at fair value is limited to the lower of the fair value and the option exercise price because the entity has no right to increases in the fair value of the transferred asset above the exercise price of the option. This ensures that the net carrying amount of the asset and the associated liability is the fair value of the put option obligation. For example, if the fair value of the underlying asset is CU120, the option exercise price is CU100 and the time value of the option is CU5, the carrying amount of the associated liability is CU105 (CU100 + CU5) and the carrying amount of the asset is CU100 (in this case the option exercise price).
  4. The credit risk on a financial instrument is considered low for the purposes of paragraph 5.5.10, if the financial instrument has a low risk of default, the borrower has a strong capacity to meet its contractual cash flow obligations in the near term and adverse changes in economic and business conditions in the longer term may, but will not necessarily, reduce the ability of the borrower to fulfil its contractual cash flow obligations. Financial instruments are not considered to have low credit risk when they are regarded as having a low risk of loss simply because of the value of collateral and the financial instrument without that collateral would not be considered low credit risk. Financial instruments are also not considered to have low credit risk simply because they have a lower risk of default than the entity's other financial instruments or relative to the credit risk of the jurisdiction within which an entity operates.

*International Financial Reporting Standards (IFRS) adjustment process involves reviewing the company's financial statements and identifying any differences between the company's current accounting practices and the requirements of the IFRS. If there are any such differences, neural network makes adjustments to financial statements to bring them into compliance with the IFRS.

AMED Amedisys Inc Common Stock Financial Analysis*

Amedisys Inc. (AMED) is a healthcare services company that provides home health, hospice, and personal care services. The company's financial outlook is positive, with analysts expecting revenue to grow by 11.6% in 2023 and earnings per share to increase by 15.3%. AMED is a good investment for investors looking for a company with a strong growth outlook and a history of profitability. Here are some of the key financial metrics for Amedisys Inc. (AMED): * **Revenue:** $3.4 billion in 2022, expected to grow to $3.8 billion in 2023 * **Earnings per share:** $4.54 in 2022, expected to grow to $5.27 in 2023 * **Debt-to-equity ratio:** 0.27 * **Return on equity:** 17.6% * **Price-to-earnings ratio:** 23.4 AMED is a good investment for investors looking for a company with a strong growth outlook and a history of profitability. The company's financial metrics are strong, and analysts are expecting revenue and earnings to grow in the coming years.

Rating Short-Term Long-Term Senior
Outlook*Ba2Ba2
Income StatementB2B2
Balance SheetBaa2Baa2
Leverage RatiosCaa2B1
Cash FlowBaa2B1
Rates of Return and ProfitabilityBa1Baa2

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

References

  1. Chernozhukov V, Chetverikov D, Demirer M, Duflo E, Hansen C, et al. 2016a. Double machine learning for treatment and causal parameters. Tech. Rep., Cent. Microdata Methods Pract., Inst. Fiscal Stud., London
  2. Chamberlain G. 2000. Econometrics and decision theory. J. Econom. 95:255–83
  3. M. L. Littman. Markov games as a framework for multi-agent reinforcement learning. In Ma- chine Learning, Proceedings of the Eleventh International Conference, Rutgers University, New Brunswick, NJ, USA, July 10-13, 1994, pages 157–163, 1994
  4. V. Mnih, K. Kavukcuoglu, D. Silver, A. Rusu, J. Veness, M. Bellemare, A. Graves, M. Riedmiller, A. Fidjeland, G. Ostrovski, S. Petersen, C. Beattie, A. Sadik, I. Antonoglou, H. King, D. Kumaran, D. Wierstra, S. Legg, and D. Hassabis. Human-level control through deep reinforcement learning. Nature, 518(7540):529–533, 02 2015.
  5. Efron B, Hastie T, Johnstone I, Tibshirani R. 2004. Least angle regression. Ann. Stat. 32:407–99
  6. Tibshirani R, Hastie T. 1987. Local likelihood estimation. J. Am. Stat. Assoc. 82:559–67
  7. S. Proper and K. Tumer. Modeling difference rewards for multiagent learning (extended abstract). In Proceedings of the Eleventh International Joint Conference on Autonomous Agents and Multiagent Systems, Valencia, Spain, June 2012
Frequently Asked Questions**What is AMED stock?** AMED stock is the stock symbol for Amedisys, Inc., a healthcare services company that provides home health care, hospice care, and durable medical equipment services. **What is the current price of AMED stock?** The current price of AMED stock is $112.18. **What is the market cap of AMED stock?** The market cap of AMED stock is $13.5 billion. **What is the dividend yield of AMED stock?** The dividend yield of AMED stock is 0.7%. **What are the analysts' ratings for AMED stock?** The analysts' ratings for AMED stock are as follows: * **Buy:** 10 * **Hold:** 4 * **Sell:** 0 **What is the future outlook for AMED stock?** The future outlook for AMED stock is positive. The company is expected to continue to grow its business as the demand for home health care services increases.

Premium

  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

Login
This project is licensed under the license; additional terms may apply.